Claudin 18.2 ADCs Demonstrate Early Clinical Promise

Phase I trials of two Claudin 18.2-targeted antibody–drug conjugates (ADC) show promising activity in advanced gastric and gastroesophageal junction cancers. The ADCs differ in their structure but showed similar efficacy and safety, and both might offer advantages over currently approved immunotherapies.

Publication Details

Journal
Cancer Discovery
Published
2025-01-01
DOI
https://doi.org/10.1158/2159-8290.cd-nw2025-0069
Primary Topic
Barrier Structure and Function Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Claudin 18.2 ADCs Demonstrate Early Clinical Promise

Cancer Discovery
Barrier Structure and Function Studies
article

Claudin 18.2 ADCs Demonstrate Early Clinical Promise

article en

Abstract

Phase I trials of two Claudin 18.2-targeted antibody–drug conjugates (ADC) show promising activity in advanced gastric and gastroesophageal junction cancers. The ADCs differ in their structure but showed similar efficacy and safety, and both might offer advantages over currently approved immunotherapies.

Cancer Discovery
Zero hunger
Openalex Percentile: Top 72%
Barrier Structure and Function Studies
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Claudin 18.2 ADCs Demonstrate Early Clinical Promise · Cancer Discovery (2025) | TGRS Research Map | TGRS